Immunic Inc (IMUX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunic Inc (IMUX) has a cash flow conversion efficiency ratio of 2.889x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.28 Million) by net assets ($-6.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Immunic Inc market capitalisation for the company's overall valuation and market capitalisation.
Immunic Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Immunic Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immunic Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunic Inc ranked by their cash flow conversion efficiency. See IMUX debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Speed Tech
TWO:5457
|
0.025x |
|
JIUMAOJIU INTL HLDGS LTD
F:3YU
|
N/A |
|
Manali Petrochemicals Limited
NSE:MANALIPETC
|
0.028x |
|
Hemisphere Energy Corporation
V:HME
|
0.193x |
|
Naturhouse Health SA
MC:NTH
|
0.224x |
|
PERENNIAL ENERGY HD-01
F:PEZ
|
N/A |
|
Emilia Devel
TA:EMDV
|
0.066x |
|
Ilex Medical
TA:ILX
|
0.039x |
Annual Cash Flow Conversion Efficiency for Immunic Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Immunic Inc from 2011 to 2025. View Immunic Inc (IMUX) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.67 Million | $-85.81 Million | 12.859x | +379.56% |
| 2024-12-31 | $18.43 Million | $-84.77 Million | -4.600x | -87.88% |
| 2023-12-31 | $28.93 Million | $-70.83 Million | -2.448x | -327.23% |
| 2022-12-31 | $113.68 Million | $-65.14 Million | -0.573x | +12.49% |
| 2021-12-31 | $127.11 Million | $-83.23 Million | -0.655x | -125.41% |
| 2020-12-31 | $158.78 Million | $-46.12 Million | -0.290x | +40.61% |
| 2019-12-31 | $58.36 Million | $-28.55 Million | -0.489x | +85.92% |
| 2018-12-31 | $12.43 Million | $-43.16 Million | -3.473x | -330.30% |
| 2017-12-31 | $50.04 Million | $-40.40 Million | -0.807x | -31.88% |
| 2016-12-31 | $58.45 Million | $-35.77 Million | -0.612x | -0.88% |
| 2015-12-31 | $82.33 Million | $-49.95 Million | -0.607x | -45.00% |
| 2014-12-31 | $97.56 Million | $-40.83 Million | -0.418x | +39.50% |
| 2013-12-31 | $41.42 Million | $-28.65 Million | -0.692x | -157.11% |
| 2012-12-31 | $-7.63 Million | $-9.24 Million | 1.211x | +748.41% |
| 2011-12-31 | $-54.85 Million | $-7.83 Million | 0.143x | -- |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more